GeneDx Holdings Corp (WGS)

Currency in USD
45.46
-3.78(-7.68%)
Closed·
46.35+0.89(+1.96%)
·
Advertisement
WGS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
45.1649.10
52 wk Range
32.21170.87
Key Statistics
Prev. Close
45.46
Open
47.95
Day's Range
45.16-49.1
52 wk Range
32.21-170.87
Volume
912.64K
Average Volume (3m)
862.82K
1-Year Change
-68.9799%
Book Value / Share
8.20
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
WGS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
82.00
Upside
+80.38%
Members' Sentiments
Bearish
Bullish
ProTips
6 analysts have revised their earnings downwards for the upcoming period

GeneDx Holdings Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 82.00
(+80.38% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Craig-Hallum
Buy66.00+45.18%103.00Maintain13/11/2026
BTIG
Buy85.00+86.98%90.00Maintain10/11/2026
Guggenheim
Buy83.00+82.58%74.00Maintain01/10/2026
Canaccord
Buy90.00+97.98%75.00Maintain04/08/2026
Guggenheim
Buy74.00+62.78%70.00Maintain29/06/2026

GeneDx Holdings Corp Earnings Call Summary for Q3/2026

  • GeneDx Q3 revenue hit $123.1M, matching estimates, but missed EPS at -$0.41 vs. $0.07 forecast; shares fell 8.25% after hours to $60.3.
  • Adjusted gross margin expanded to 72% from 70% in Q2; adjusted net income turned positive at $8.6M, up from $8.2M loss in Q1.
  • Company raised FY adjusted gross margin guidance to ~71% and net income to at least $12M; reaffirmed revenue at $475M-$490M, low end expected.
  • Q4 guidance: revenue of at least $135M, exome/genome revenue of $121M, adjusted net income of ~$12M, and 34,500 test volume.
  • Revenue-cycle overhaul prioritizing paid volume over raw growth may pressure near-term results; PAMA headwind expected in 2027 offset by RCM gains.
Last Updated: 09/11/2026, 22:36
Read Full Transcript

Earnings

Latest Release
09/11/2026
EPS / Forecast
-0.41 / 0.07
Revenue / Forecast
123.1M / 122.98M
EPS Revisions
Last 90 days

Compare WGS to Peers and Sector

Metrics to compare
WGS
Peers
Sector
Relationship
P/E Ratio
−12.3x−33.9x−0.2x
PEG Ratio
0.00−0.050.00
Price/Book
5.6x2.8x2.6x
Price / LTM Sales
3.0x2.9x2.6x
Upside (Analyst Target)
80.4%37.7%76.9%
Fair Value Upside
Unlock−2.3%14.9%Unlock

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
9.09M30.32%472.17M
Other Institutional Investors
27.62M69.68%1.43B
Public Companies & Retail Investors
0.000.00%0.00
Total
36.7M100.00%1.91B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Corvex Management LP15.96%4,784,570248,606
Casdin Capital, LLC12.37%3,707,164192,624

People Also Watch

14.270
PSNL
-3.06%
109.57
ROG
-9.03%
163.81
RGEN
-3.81%
12.39
BHVN
-9.23%
21.73
TNGX
-4.32%

FAQ

What Is the GeneDx Holdings (NASDAQ: WGS) Share Price Today?

The GeneDx Holdings stock price today is 45.46 USD.

What Stock Exchange Does GeneDx Holdings (WGS) Trade On?

GeneDx Holdings is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for GeneDx Holdings?

The stock symbol (also called a 'ticker') for GeneDx Holdings is "WGS."

What Is the Current GeneDx Holdings Market Capitalisation?

As of today, GeneDx Holdings (NASDAQ: WGS) market cap is 1.48B USD.

What Is GeneDx Holdings's (WGS) Earnings Per Share (TTM)?

The GeneDx Holdings EPS is currently -3.76 (Trailing Twelve Months).

When Is the Next GeneDx Holdings Earnings Date?

GeneDx Holdings's next earnings report will be released on 16/03/2027.

Is WGS a Buy or Sell From a Technical Analyst Perspective?

Based on today's GeneDx Holdings moving averages and other technical indicators, the daily buy/sell signal for WGS stock is Strong Sell.

How Many Times Has GeneDx Holdings Stock Split?

GeneDx Holdings has split 1 times. (See the WGS stock split history page for full effective split date and price information.)

How Many Employees Does GeneDx Holdings Have?

GeneDx Holdings has 1300 employees, based on their latest Companies House report.

What is the current trading status of GeneDx Holdings (NASDAQ: WGS)?

As of 21/11/2026, GeneDx Holdings (WGS) is trading at a share price of 45.46 USD, with a previous close of 45.46 USD. The stock has fluctuated within a day range of 45.16 USD to 49.10 USD, while its 52-week range spans from 32.21 USD to 170.87 USD.

What Is GeneDx Holdings (WGS) Price Target According to Analysts?

The average 12-month price target for GeneDx Holdings is 82.00 USD, with a high estimate of 102 USD and a low estimate of 65 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +80.38% Upside potential.

What Is the WGS Premarket Price?

WGS's last pre-market stock price is 48.00 USD. The pre-market share volume is 5,190.00, and the stock has decreased by -1.24, or -2.52%.

What Is the WGS After Hours Price?

WGS's last after hours stock price is 46.35 USD, the stock has decreased by 0.89, or 1.96%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.